Novartis gains CHMP support in MS, Cushing syndrome

By Jonathan Block, Associate Editor | Nov 16, 2019 | 12:27 AM GMT

Included November roundup of EMA’s CHMP were a positive opinion for Mayzent siponimod, which Novartis hopes will